Exploring How Toxic Oligomer Biomarkers Can Improve Early Detection & Monitoring in Alzheimer’s & Parkinson’s Disease
9:30 am - Wednesday 2nd December 2026
- Explore how AltPep’s toxic oligomer assays perform alongside established biomarkers such as pTau217 and what each biomarker reveals about disease initiation, progression and pathology
- Examine the commonalities and distinctions between Alzheimer’s and Parkinson’s disease, discussing how disease-specific toxic oligomer biomarkers can differentiate AD, PD and mixed pathology while providing insights into shared mechanisms of protein misfolding and aggregation
- Explore the role of biomarkers in next-generation clinical trials, including how measuring disease-driving toxic oligomers can support earlier patient identification, improve stratification strategies and potentially serve as a tool for monitoring therapeutic response alongside AltPep’s therapeutic programme
